Denali Therapeutics executive Alexander O. Schuth sold 2,768 shares at $23.44 each on September 1, 2026. The transaction leaves Schuth owning 278,995 Denali shares, giving investors the disclosed post-transaction ownership figure for the company’s COFO and secretary.
Key Highlights
- The reported transaction price was $23.44 per share.
- Alexander O. Schuth retained 278,995 Denali Therapeutics shares after the sale.
- The share transaction occurred on September 1, 2026.
Denali Therapeutics Inc. (NASDAQ: DNLI) executive Alexander O. Schuth sold 2,768 shares in a transaction involving the company’s stock. Schuth serves as Denali’s COFO and secretary.
$23.44 Per-Share Sale Leaves 278,995 Shares
The transaction carried a price of $23.44 for each share sold. His disclosed ownership after the transaction stood at 278,995 shares. The reported figures cover the shares sold, the per-share transaction price and Schuth’s remaining Denali holdings. Schuth’s post-transaction position was therefore stated at 278,995 shares. The disclosed ownership figure follows the sale of 2,768 shares.
FAQs
Q: How many Denali Therapeutics shares did Alexander Schuth sell?
A: Alexander O. Schuth sold 2,768 Denali Therapeutics shares. The reported transaction price was $23.44 per share on September 1, 2026.
Q: What is the disclosed impact of the Denali Therapeutics executive share sale?
A: Following the sale of 2,768 Denali Therapeutics shares at $23.44 per share on September 1, 2026, Alexander O. Schuth’s disclosed post-transaction ownership was 278,995 shares.
Q: How many shares does Alexander Schuth own after selling DNLI stock?
A: Alexander O. Schuth owned 278,995 Denali Therapeutics shares after the transaction. He is identified as the company’s COFO and secretary.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.